Total Net Assets: PROCEPT BioRobotics Corp (PRCT)

This chart illustrates PROCEPT BioRobotics (PRCT), a leader in robotic urology with an impeccable reputation among physicians. The asset value tracked on the chart, which currently stands at 0.34, is supported by high margins on consumables and clinic dependency on the software. However, international disputes and chip shortages are hindering the production of complex systems, limiting the brand's expansion into closed markets.

As the AquaBeam system aggressively displaces laser surgery, the cost of capital on the balance sheet reflects the financial stability of PROCEPT BioRobotics (PRCT) while scaling innovations. This metric captures the difference between total assets and all liabilities, demonstrating the actual equity value of the business, which allows investors to assess default risk and capital management efficiency during a period of high borrowing costs.